“…It is clearly established that ROS can promote coagulation through several means, such as enhancing the expression of tissue factor in endothelial cells, monocytes, and vascular smooth muscle cells, interfering with platelet activation, and causing oxidative structural and functional alterations to crucial proteins involved in the coagulation cascade (e.g., tissue factor pathway inhibitor (TFPI), protein C, thrombomodulin, fibrinogen, antithrombin) ( Gray and Barrowcliffe, 1985 ; Glaser et al, 1992 ; Freedman et al, 1999 ; Van Patten et al, 1999 ; Ohkura et al, 2004 ; Nalian and Iakhiaev, 2008 ; Pensalfini et al, 2008 ; Barr et al, 2013 ; Barygina et al, 2013 ; Becatti et al, 2013 ; Becatti et al, 2015 ; Dayal et al, 2015 ; Becatti et al, 2016b ; Becatti et al, 2017 ; Barygina et al, 2019a ; Barygina et al, 2019b ; Becatti et al, 2019b ; Emmi et al, 2019b ; Becatti et al, 2020 ; Branca et al, 2020 ; Cito et al, 2020 ; Ianni et al, 2021 ; Mannucci et al, 2021 ; Bettiol et al, 2022 ; Becatti et al, 2023 ). Additionally, ROS can facilitate thrombo-inflammation, including via hyperactivation of leukocytes, particularly neutrophils, and the release of neutrophil extracellular traps (NETs) ( Bettiol et al, 2021 ).…”